Psychometric properties of a condition-specific PROM for the psychosocial consequences of Labelling hypertension by using Rasch analysis

Imagem de Miniatura
Arquivos
art_GYURICZA_Psychometric_properties_of_a_conditionspecific_PROM_for_the_2021.PDF (507.42 KB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPRINGERNATURE
Autores
CHRISTENSEN, Karl Bang
BRODERSEN, John
Citação
JOURNAL OF PATIENT-REPORTED OUTCOMES, v.5, n.1, article ID 19, 17p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background A previous qualitative assessment of the psychosocial consequences of labelling hypertension describes the diagnosis of hypertension as a labelling event with potential unintended negative long-term psychosocial consequences (labelling effects). Until now, the benefits of diagnosing hypertension have been far more reported than the harms. To obtain the net result of the preventive interventions for cardiovascular disease, such as diagnosing and treating mild hypertension, assessing benefits and harms in the most comprehensive way possible is necessary, including the psychosocial consequences of labelling. When measuring psychosocial consequences of labelling hypertension, a questionnaire with high content validity and adequate psychometric properties is needed. Objectives The aim of this study was to describe the psychometric parameters of face and content-validated pool of items. Other objectives were also to screen the item pool by using Rasch model analysis and confirmatory factor analysis (CFA) for identifying such items with sufficient fit to the hypothesised models. Methods We surveyed the pool of items as a draft questionnaire to Brazilians recruited via social networks, sending e-mails, WhatsApp (R) messages and posting on Facebook (R). The inclusion criteria were to be older than 18 years old, to be healthy and to have only hypertension. We used Rasch model analysis to screen the item pool, discarding items that did not fit the hypothesised domain. We searched for local dependence and differential item functioning. We used CFA to confirm the derived measurement models and complementarily assessed reliability using Cronbach's coefficient alpha. Results The validation sample consisted of 798 respondents. All 798 respondents completed Part I, whereas 285 (35.7%)-those with hypertension-completed Part II. A condition-specific questionnaire with high content validity and adequate psychometric properties was developed for people labelled with hypertension. This measure is called 'Consequences of Labelling Hypertension Questionnaire' and covers the psychosocial consequences of labelling hypertension in two parts, encompassing a total of 71 items in 15 subscales and 11 single items. Conclusion We developed a tool that can be used in future research involving hypertension, especially in scenarios of screening, prevention, population strategies and in intervention studies. Future use and testing of the questionnaire may still be required.
Palavras-chave
Hypertension, Psychosocial consequences, Patient-reported outcome, Psychometric properties
URI
https://observatorio.fm.usp.br/handle/OPI/43969
Referências
  1. ANDERSEN EB, 1973, BRIT J MATH STAT PSY, V26, P31, DOI 10.1111/j.2044-8317.1973.tb00504.x
  2. Andrich D, 2004, MED CARE, V42, P7, DOI 10.1097/01.mlr.0000103528.48582.7c
  3. BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
  4. Brodersen J, 2004, J MED SCREEN, V11, P39, DOI 10.1258/096914104772950745
  5. Brodersen J., 2007, J MED ECON, V10, P309, DOI [DOI 10.3111/13696990701557048, 10.3111/13696990701557048]
  6. Brodersen JDL., 2013, RASCH MODELS HLTH, DOI [10.1002/9781118574454.ch15, DOI 10.1002/9781118574454.CH15]
  7. Brodersen J, 2008, SCAND J PRIM HEALTH, V26, P251, DOI 10.1080/02813430802542508
  8. Brodersen J, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-3
  9. Brodersen John, 2017, J Patient Rep Outcomes, V2, P37, DOI 10.1186/s41687-018-0066-1
  10. Brodersen John, 2018, BMC Psychol, V6, P39, DOI 10.1186/s40359-018-0251-2
  11. Brodersen J, 2010, VALUE HEALTH, V13, P601, DOI 10.1111/j.1524-4733.2010.00697.x
  12. Cho E, 2015, ORGAN RES METHODS, V18, P207, DOI 10.1177/1094428114555994
  13. Christensen K. B, 2002, STAT METHODS QUALITY, P187, DOI [10.1007/978-1-4757-3625-0_15, DOI 10.1007/978-1-4757-3625-0_15]
  14. Christensen KB, 2017, APPL PSYCH MEAS, V41, P178, DOI 10.1177/0146621616677520
  15. Christensen KB., 2013, RASCH MODELS HLTH
  16. Comins J, 2008, SCAND J MED SCI SPOR, V18, P336, DOI 10.1111/j.1600-0838.2007.00724.x
  17. Cote Isabelle, 2004, Can J Clin Pharmacol, V11, pe232
  18. GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644
  19. Gyuricza JV, 2019, J PATIENT-REP OUTCOM, V4, DOI 10.1186/s41687-019-0168-4
  20. Hagell P, 2009, VALUE HEALTH, V12, P613, DOI 10.1111/j.1524-4733.2008.00488.x
  21. Hamer M, 2010, HYPERTENSION, V56, P547, DOI 10.1161/HYPERTENSIONAHA.110.153775
  22. HAYNES RB, 1978, NEW ENGL J MED, V299, P741, DOI 10.1056/NEJM197810052991403
  23. Hobart JC, 2002, STROKE, V33, P1348, DOI 10.1161/01.STR.0000015030.59594.B3
  24. Holland PW., 1993, ED TESTING SERVICE D, pXV
  25. Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424
  26. Kaplan RM, 2007, ANNU REV PUBL HEALTH, V28, P321, DOI 10.1146/annurev.publhealth.28.021406.144141
  27. Kreiner S., 2013, 1306 U COP COP DEP B
  28. Kreiner S, 2007, NORD PSYCHOL, V59, P268, DOI 10.1027/1901-2276.59.3.268
  29. Kreiner S, 2007, STAT SOC BEHAV SC, P329, DOI 10.1007/978-0-387-49839-3_21
  30. Krogsboll LT, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009009.pub3
  31. Linden WJ., 1997, HDB MODERN ITEM RESP, pXV, DOI [10.1007/978-1-4757-2691-6, DOI 10.1007/978-1-4757-2691-6]
  32. MACDONALD LA, 1984, J CHRON DIS, V37, P933, DOI 10.1016/0021-9681(84)90070-5
  33. MOSSEY JM, 1981, CLIN INVEST MED, V4, P201
  34. Nguyen TH, 2014, PATIENT, V7, P23, DOI 10.1007/s40271-013-0041-0
  35. Ogedegbe G, 2010, HYPERTENSION, V56, P344, DOI 10.1161/HYPERTENSIONAHA.110.156257
  36. PICKERING G, 1978, J ROY SOC MED, V71, P885, DOI 10.1177/014107687807101207
  37. Rasch G., 1960, PROBABILISTIC MODELS
  38. Sangren H, 2009, PATIENT EDUC COUNS, V74, P236, DOI 10.1016/j.pec.2008.08.007
  39. Snyder CF, 2013, MED CARE, V51, pS73, DOI 10.1097/MLR.0b013e31829b1d84
  40. TENNANT A, 1995, BRIT J RHEUMATOL, V34, P899
  41. Tennant A, 2004, VALUE HEALTH, V7, pS22, DOI 10.1111/j.1524-4733.2004.7s106.x
  42. Vinther JL, 2013, DAN MED J, V60
  43. Vos T, 2016, LANCET, V388, P1545, DOI 10.1016/S0140-6736(16)31678-6
  44. Wiebe S, 2003, J CLIN EPIDEMIOL, V56, P52, DOI 10.1016/S0895-4356(02)00537-1
  45. Wright B D, 2000, J Appl Meas, V1, P83

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPR
Artigos e Materiais de Revistas Científicas - LIM/39
Artigos e Materiais de Revistas Científicas - ODS/03